Clinical Trials
18 trialsNCT05902169 2026-06-05
SONOBIRD
CarThera
Phase 3 Recruiting
NCT07326566 2026-06-05
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Black Diamond Therapeutics, Inc.
Phase 2 Recruiting
NCT03514069 2026-06-04
Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma
Case Comprehensive Cancer Center
Phase 1 Completed
NCT07223034 2026-06-04
A Study of 177Lu-PSMA-617 in People With Gliomas
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT02152982 2026-06-03
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT03970447 2026-06-03
GBM AGILE
Global Coalition for Adaptive Research
Phase 2/3 Recruiting
NCT03213002 2026-06-01
CAPTEM
Northwell Health
Phase 1/2 Recruiting
NCT05271240 2026-06-01
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
Northwell Health
Phase 3 Recruiting
NCT05843253 2026-05-29
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Phase 2 Recruiting
NCT06831526 2026-05-29
Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma
Washington University School of Medicine
Phase EARLY_PHASE1 Recruiting
NCT07195591 2026-05-29
BRIDGES
GT Medical Technologies, Inc.
Phase 3 Recruiting
NCT05765812 2026-05-28
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Debiopharm International SA
Phase 1/2 Recruiting
NCT03581292 2026-05-27
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03688178 2026-05-22
DERIVe
Duke University
Phase 2 Active not recruiting
NCT05109728 2026-05-22
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
Novartis
Phase 1 Active not recruiting
NCT04555577 2026-05-20
Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05095376 2026-05-19
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NRG Oncology
Phase 3 Active not recruiting
NCT05432804 2026-05-18
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
National Cancer Institute (NCI)
Phase 1/2 Recruiting